News

The companies have entered into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation Technology to develop CRISPR/Cas9-based therapies in immuno-oncology. CRISPR

Aimmune Therapeutics is engaged in the development of advanced treatments for life-threatening food allergies. The latest investment brings Nestlé’s total investment in the drug developer for food allergies

The priority review for Lynparza (olaparib) is for the maintenance treatment of such patients who had shown complete or partial response after first-line standard platinum-based chemotherapy. The FDA

OrbiMed served as the lead new investor, along with new investors Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures (LAV) and NS Investment. Harpoon’s existing investors MPM Capital, Oncology

Now available by prescription in pharmacies across the US, NOCDURNA provides adults with a fast-acting, effective treatment that targets the kidneys, the underlying cause of NP. The sublingual

GS-9674 is an investigational, selective and non-steroidal agonist of the (FXR), which is a nuclear hormone receptor that is highly expressed in the gastrointestinal tract and liver. FXR

It follows the successful completion of milestones set in the initial Phase 1 grant for $223,000, awarded in 2016. Both grants focus on a process known as cellular

VIS649 is a monoclonal antibody targeting the B-cell growth factor APRIL (A Proliferation Inducing Ligand) for the potential treatment of imumuglobulin A nephropathy (IgA nephropathy or IgAN), one

The merger of BioTime and Asterias Biotherapeutics will enable to create a major cell therapy company. As per terms of the deal, Asterias stockholders will secure 0.71 common